Allergan to buy fat-fighter Zeltiq Aesthetics for $2.48 billion
Allergan said it would benefit from the cross-selling opportunities for consumers of Zeltiq's CoolSculpting System, which uses cooling to kill fat cells, as well as customers of its own facial injectible products. "Demand for both procedures is high and this is similar to pouring more gas on the fire," Allergan Chief Commercial Officer Bill Meury said on a call with investors.
